Brigatinib Versus Alectinib in ALK-Positive NSCLC After Disease Progression on Crizotinib: Results of Phase 3 ALTA-3 Trial

CHIH-HSIN YANGLiu, GeoffreyGeoffreyLiuLu, ShunShunLuHe, JianxingJianxingHeBurotto, MauricioMauricioBurottoAhn, Myung-JuMyung-JuAhnKim, Dong-WanDong-WanKimLiu, XiaoQingXiaoQingLiuZhao, YanqiuYanqiuZhaoVincent, SylvieSylvieVincentYin, JianiJianiYinMa, XinXinMaLin, Huamao MHuamao MLinPopat, SanjaySanjayPopat2023-09-252023-09-252023-08-1215560864https://scholars.lib.ntu.edu.tw/handle/123456789/635778This open-label, phase 3 trial (ALTA-3; NCT03596866) compared efficacy and safety of brigatinib versus alectinib for ALK+ NSCLC after disease progression on crizotinib.enAlectinib; Anaplastic lymphoma kinase; Brigatinib; Non–small cell lung cancer; Tyrosine kinase inhibitorBrigatinib Versus Alectinib in ALK-Positive NSCLC After Disease Progression on Crizotinib: Results of Phase 3 ALTA-3 Trialjournal article10.1016/j.jtho.2023.08.010375741322-s2.0-85171148033https://api.elsevier.com/content/abstract/scopus_id/85171148033